Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:SLS News 18 October 2025 - 2 January 2026

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility. As of 12:22 UTC on Tuesday, Dec. 23, 2025, SLS stock traded around $2.64, according to market data. In the prior session, the stock closed around $2.64 after moving sharply higher on heavy volume (roughly 8.9 million shares)—a notable burst for a small-cap biotech. Investing.com So what’s behind the renewed attention? In short: SELLAS just presented updated Phase 2 AML data for SLS009 at ASH 2025,
23 December 2025
·
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (NASDAQ: SLS) stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech (versus a 52-week low of $0.77). In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new 52-week high ts2.tech. Big investors are piling in: BlackRock disclosed a 5.4% stake (~5.7M shares) in SLS on Oct. 18 ts2.tech, and other funds like Vanguard and Marshall Wace added millions of shares in Q2 quiverquant.com. On the drug-development front, Sellas’s lead AML immunotherapy (galinpepimut‑S, “GPS”) is in a Phase 3 AML trial (REGAL), which recently passed an interim safety review
20 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 stockanalysis.com marketbeat.com. Trading volume and volatility have picked up – for instance, on Oct. 14 a massive spike in call-option activity (761% above average) coincided with bullish sentiment marketbeat.com. The stock’s YTD gain (~100%) far outpaces many small-cap biotechs. Technical platforms note SLS is in “uptrend” territory: the stock is well above its 20-day EMA ($1.89) and 50-day EMA ($1.81) tipranks.com, which TipRanks flags
18 October 2025
··
BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

Key Facts – October 18, 2025 Stock Performance: SLS on a Tear in 2025 SELLAS Life Sciences’ stock has been on a remarkable run this year. Shares have effectively doubled in 2025, and the momentum accelerated in mid-October. On Friday Oct. 17, SLS closed at $2.14, up roughly 100% year-to-datefinbold.com. In fact, during that day’s session the stock touched a 52-week high of $2.27 (more than 3× its 52-week low of $0.77)marketbeat.com. Trading activity exploded as well – volume spiked to several times the usual level (over 6.7 million shares vs ~2.2M average) amid a flurry of speculative buying. Options
18 October 2025

Stock Market Today

Agricultural Bank of China 601288 A-shares slide as tech rout bites; inflation data is the next test

Agricultural Bank of China 601288 A-shares slide as tech rout bites; inflation data is the next test

7 February 2026
Agricultural Bank of China’s A shares closed down 0.45% at 6.67 yuan in Shanghai Friday, with turnover at 2.24 billion yuan. The bank’s A-share capital remained unchanged at 319.24 billion shares as of Jan. 31. Mainland and Hong Kong stocks fell after a global tech selloff and a sharp drop in silver futures. China’s January CPI data is due Feb. 11, with trading expected to thin ahead of the Lunar New Year break.
Palantir stock price rebounds after AI shakeout — what traders watch next week

Palantir stock price rebounds after AI shakeout — what traders watch next week

7 February 2026
Palantir Technologies shares rose 4.5% to $135.90 Friday after reporting a 70% jump in Q4 revenue to $1.407 billion and forecasting 61% revenue growth in 2026. The stock rebounded from a 6.8% drop Thursday, triggered by concerns over Big Tech capital spending and AI’s impact on software demand. A new partnership with Cognizant and U.S. government policy shifts kept Palantir in focus. Director Alexander D. Moore sold 20,000 shares on Feb. 2.
Go toTop